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OXIDATIVE damage is involved in the pathogenic proc-
ess  of  idiopathic  chronic  inflammatory  bowel  dis-
ease. Although specific intervention in the oxidative
cascade showed promising results in animal models
and preliminary patient trials, the clinical efficacy of
antioxidants still has to be established. Mucosa pro-
tection, for example by dietary fatty acids, seems to
attenuate the intestinal inflammatory process as well
but awaits definite clinical proof for the treatment of
inflammatory bowel disease
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Introduction
The aetiology of Crohn’s disease (CD) and ulcerative
colitis  (UC),  the two forms of  inflammatory  bowel
disease (IBD), remains as yet unknown, which ham-
pers  the  development  of  innovative,  custom-made
IBD therapies. Existing therapies are often aimed at
general  mediators  or  mechanisms  of  inflammation.
Over  the  past  decades,  however,  knowledge  of
particular  molecular, biochemical and inflammatory
events  in  IBD  has  increased  considerably.  New
concepts  explaining  how  these  events  relate  to
intestinal tissue damage have led to new potentially
effective treatment strategies for IBD aimed at coun-
teracting oxidative stress or providing mucosa protec-
tion.  Some  of  these  therapies  were  found  to  have
clinical  success  while  others  have  already  been
abandoned again, as will be discussed in this short
selective review.
Antioxidants
A  growing  body  of  evidence  indicates  excessive
production of reactive oxygen metabolites (ROMs) as
a direct or indirect cause of mucosal tissue damage in
IBD (reviewed in Yamada and Grisham1). The princi-
pal  source  of  ROMs  in  IBD  are  the  phagocytic
leukocytes.  During  episodes  of  inflammation  these
cells massively infiltrate the intestinal mucosa, where
on  activation  they  synthesize  and  release  large
amounts of ROMs. Another major ROM producer is
the  epithelial  and  endothelial  cell-derived  enzyme
xanthine  oxidase. This  enzyme  is  formed  and  acti-
vated after periods of ischaemia and reperfusion, a
process implicated in the vasculitis-associated micro-
infarctions at the intestinal level which are thought to
contribute to the pathogenesis of IBD, particularly in
CD.
The  chronic  nature  of  IBD  implies  an  enduring
tissue  exposure  to  ROMs.  Although  the  intestinal
mucosa  contains  a  wide  variety  of  endogenous
antioxidant  defence  mechanisms,  their  levels  are
relatively low compared with those in other organs
(e.g.  liver,  lung).  Moreover,  the  efficacy  of  these
systems may be impaired during inflammation, partly
as a result of autooxidation. Thus, IBD mucosa may be
in a constant state of oxidative stress, posing a serious
threat to intestinal tissue homeostasis.
Interestingly,  attenuating  oxidative  stress  has  for-
tuitously  already  been  a  therapeutic  strategy  for
almost  50  years.  Commonly  used  drugs  in  the
treatment of IBD, in particular sulphasalazine and its
active  moiety  5-aminosalicylic  acid  (5-ASA),  were
found to be potent ROM scavengers. However, this
mechanism is just one of the many pharmacological
actions of these agents. It may be clinically relevant to
develop therapies specifically aimed at re-balancing
the oxidative homeostasis in IBD.
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The  cascade  of  ROM  production  (see  Fig.  1)  is
initiated with the formation of the superoxide anion
(O–
2)  by  a  one-electron  reduction  of  oxygen.  O–
2
itself  is  a  relatively  unharmful  oxidant,  but  it  is
dismutated spontaneously or enzymatically by super-
oxide  dismutase  (SOD)  to  yield  the  more  reactive
metabolite  hydrogen  peroxide  (H 2O2).  The  easily
diffusable  and  rather  long-lived  H 2O2 is  intracellu-
larly detoxified to water by the enzymes catalase or
glutathione peroxidase. However, H 2O2 can also be
metabolized to  the  secondary ROMs  hydroxyl radi-
cal  (OH￿)  and  hypochlorous  acid  (HOCl).  OH￿,
formed  by  the  combination  of  O–
2 and  H2O2 in  a
metal  catalysed reaction, is extremely reactive with
virtually  every  molecule  it  encounters.  HOCl  is
formed  via  the  action  of  myeloperoxidase  (MPO)
from activated phagocytes and is a powerful  ROM,
with  strong  oxidizing and  chlorinating  capabilities.
Hypochlorous acid is also known to inactivate pro-
tease inhibitors (e.g. a 1-antitrypsin), which disturbs
the  proteinase–antiproteinase  balance  and  leads  to
propagation of extracellular matrix degradation and
mucosal  tissue damage.
Strategies of antioxidant therapy
In  the  past  decade,  a  slowly  increasing  amount  of
literature emerged on the evaluation of drug-induced
intervention strategies, specifically aimed at preven-
tion or attenuation of intestinal oxidative stress (see
Table  1  and  Fig.  1).  Basically,  these  approaches
include inhibition of ROM producing enzymes, direct
scavenging  of  ROMs,  or  improvement  of  cellular
antioxidant pools. Most investigations, however, used
animal models of colitis, whereas specific antioxidant
trials in IBD patient groups are rare.
The principal ROMs involved in tissue damage in
IBD  or  induced  colitis  in  animals  have  not  been
defined.  Theoretically,  the  most  promising  thera-
peutic antioxidant compounds would be those agents
which  would  decimate  the  O–
2 production,  thus
aborting the ROM cascade. Production of O–
2 can be
decreased by administration  of  allopurinol,  an  effi-
cient inhibitor of xanthine oxidase. In UC patients,
allopurinol has been reported to intensify the efficacy
of  sulphasalazine/prednisolone  regimens,2 and  to
prevent or terminate pouchitis.3 Furthermore, in rats
the  severity  of  colonic  inflammation  induced  by
acetic acid or mitomycin C was moderately reduced
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FIG. 1. Simplified schematic representation of mucosa protective and antioxidant treatment strategies in IBD. For detailed
explanation, see text. CAT, catalase; GPO, glutathione peroxidase; MPO, myeloperoxidase; SOD, superoxide dismutase; XO,
xanthine oxidase.after  treatment  with  allopurinol.4,5 Two  other  xan-
thine oxidase inhibitors were found to be ineffective,4
suggesting that xanthine oxidase is not a major ROM
source in colitis. The protective effects of allopurinol
were  explained  by  its  known  intrinsic  ability  to
scavenge O–
2.
Indeed,  direct  O–
2 scavenging  has  proved  to  be
beneficial  in  several  studies.  Preliminary  studies
reported amelioration6 or even prevention7 of colitis
induction in rodents upon treatment with free human
SOD. In two preliminary, uncontrolled clinical trials,
high  positive  response  rates  were  observed  in
patients with severe CD that had been treated with
free  or  liposomal-encapsulated  bovine  copper/zinc
SOD.8,9 Although these earlier results were encourag-
ing,  no  further  SOD-based  clinical  trials  in  IBD
patients  have  been  reported  for  almost  10  years.
Conceivably, this may point to certain limitations of
the  therapeutical  applicability  of  SOD. There  have
been attempts to increase the enzyme’s potential by
coupling SOD to carrier molecules to increase its half-
life, without affecting its specific activity. However,
SOD coupled to polyethyleneglycol or lecithin did not
show convincingly better efficacies in the treatment
of chemically induced colitis in animals4,10 Another
serious impediment of SOD therapy may be its poor
tissue penetration. Recent research on SOD therapy,
therefore,  focuses  on  SOD  mimetics  with  a  high
permeability. A number of these agents (see Table 1)
have been shown to be beneficial in animal models of
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Table 1. Strategies of antioxidant therapy in animal colitis models and IBD patients
Mechanism Compound Patients/model Response Ref.
O– 2 scavenger SOD 26 CD patients s.c./i.m. bovine CuZnSOD resulted in 64% short term,
and 82%  long term positive results
8
SOD 4 CD, 4 UC
patients
i.m. bovine CuZnSOD resulted in 87% remission rates 9
SOD Acetic acid, rat,
guinea pig
R-hu-CuZnSOD enemas reduced colonic necrosis and
inflammatory cell infiltrate, associated with lower LTB4
levels. MnSOD was inactive at similar doses
6
SOD TNBS, rabbit i.v. hu-SOD prevented colitis and lowered levels of
LTB4 and PGE2
7
PEG-SOD Acetic acid, rat i.v. doses decreased inflammation. 75% of the animals
did not respond
4
lecithin-SOD DSS, rat i.v. doses suppressed progression of bloody stools,
formation of erosions, and inflammatory cell infiltrate
10
SOD mimetic,
catalase mimetic
Cu(II)2(3,5-
DIPS)4
Acetic acid, rat Oral administration decreased inflammatory scores,
associated with less diarrhoea
11
SOD mimetic TEMPOL
(nitroxide)
TNBS, rat
Acetic acid, rat
i.g. dose decreased mucosal lesion area and
inflammatory cell infiltrate
12
SOD mimetic U74006F
(lazaroid)
TNBS, rat i.g. dose decreased inflammation, edema, and ROM
production
13
SOD mimetic,
sparing of 
glutathione
Rebamipide TNBS, rat i.p. doses prevented antioxidant enzyme impairment
and reduced severity of colitis
14
OH￿  scavenger DMSO 85 UC patients Oral administration increased remission rates (within
2 weeks). Prophylactic treatment decreased relapse
rates (within 12 months)
2
DMSO Acetic acid, rat Oral administration failed to improve inflammation 4
OH￿  scavenger Deferoxamine Acetic acid, rat i.m. doses failed to improve inflammation 4
H2O2 scavenger Catalase Acetic acid, rat
Mitomycin C,
rat
i.p. doses decreased inflammation, associated with
less diarrhoea
5,11
Xanthine
oxidase inhibitor
Allopurinol 88 UC patients Oral administration increased remission rates (within
2 weeks). Prophylactic treatment decreased relapse
rates (within 12 months)
2
Allopurinol 22 UC patients Oral administration resulted in 50%  positive response
rates in acute and chronic pouchitis
3
Allopurinol Acetic acid, rat
Mitomycin C,
rat
Oral administration lowered inflammatory scores. 50%
of the animals did not respond
4,5
Sparing of
glutathione
WR-2721 Acetic acid, rat
Mitomycin C,
rat
i.p. doses improved histology, associated with less
diarrhoea
5,11
Suppletion of
trace elements
Zinc 7 CD, 7 UC
patients
Oral administration failed to restore antioxidant
enzyme levels and did not affect disease activity
17
Zinc (Z-103) TNBS, rat Oral administration reduced inflammatory scores and
normalized lipid peroxidation levels
16
DMSO, dimethylsulphoxide; DSS, dextran sodium sulphate; SOD, superoxide dismutase; TNBS, trinitrobenzenesulphonic acid.colitis, but never resulted in a complete prevention of
tissue  damage.11–14 Their  therapeutic  potential  in
patients is still to be established.
Theoretically,  antioxidant  therapy  by  SOD  may
seem conflicting since this enzyme lowers O–
2 levels
by converting O–
2 to yield the more harmful oxidant
H 2O2.  Keshavarzian  et  al.11 speculated  that  the
primary  anti-inflammatory  effect  of  exogenously
administered  SOD  is  not  its  enzymatic  ability  to
scavenge  O–
2,  but  its  antigenicity  and  subsequent
cytokine-mediated  immunostimulatory  effect.  Pro-
tective  mechanisms  of  exogenous  SOD  may  also
include prevention of OH￿ formation or prevention of
O–
2-mediated peroxidase inhibition, consequently pre-
venting harmful H 2O2 effects.
These latter suggestions imply causative roles for
H 2O2 and/or its derived ROMs. Hence, administering
H 2O2 metabolizing  enzymes  was  thought  to  have
protective  effects  in  IBD.  In  two  different  animal
models, catalase significantly improved the severity of
acute inflammation.5,11 Glutathione peroxidase is the
other  important  H 2O2 scavenging  enzyme.  Several
synthetic compounds (see Table 1) have been descri-
bed that improve histology in acetic acid- or mitomy-
cin C-induced colitis by increasing the availibility of
glutathione, the crucial cofactor for glutathione per-
oxidase.5,11,14 Furthermore, some of the earlier men-
tioned  SOD  mimetics  also  have  H 2O2 scavenging
capabilities.11,14
Although H2O2 can exist in tissues for a long time
and  diffuses  into  all  cellular  compartments,  the
deleterious effects of H 2O2 are thought to be due to
its secondarily derived ROMs OH￿ and HOCl. In UC
patients,  addition  of  the  potent  OH￿  scavenger
dimethylsulphoxide  (DMSO)  to  a  sulphasalazine/
prednisolone regimen enhanced treatment efficacy.2
In chemically induced colitis, the evidence does not
favour  a  role  for  OH￿  so  far.  Both  DMSO  and
deferoxamine,  an  iron  chelating  agent  and  OH￿
production  inhibitor,  did  not  influence  inflamma-
tion.4 These findings are in agreement with the view
that  HOCl  rather  than  OH￿  is  involved  in  ROM
mediated  tissue  damage,  particularly  in  UC.  Inter-
estingly,  HOCl  is  able  to  maintain  its  levels  by
inhibition  of  glutathione  peroxidase  and  catalase.
There have been no reports to date on the therapeu-
tical  use  of  specific  HOCl  scavengers,  like
ascorbate.
Diet
Malnutrition  is  common  in  IBD,  and  dietary  inter-
vention is often a part of IBD therapy (see Burke et
al.)15 Yet, a role of specific nutrients in manipulating
antioxidant  status  still  has  to  be  defined.  Dietary
components such as a -tocopherol (vitamin E), ascor-
bate (vitamin C), carotenoids (vitamin A), or glucose
have  in  vitro ROM  scavenging  capabilities,  but
reports concerning the beneficial antioxidant actions
of these compounds in IBD are very limited.
It  has  been  proposed  that  some  of  the  SOD
mimetics work as carriers of copper.11 necessary for
the synthesis of copper-dependent antioxidants, e.g.
SOD.  Zinc  is  an  other  essential  trace  metal  with
antioxidant  properties,  which  is  a  component  of
antioxidant metalloproteins such as SOD. Zinc defi-
ciencies  have  been  reported  in  CD,  and  although
supplementation of zinc reduced colitis in rats,16 it
was found to be ineffective in IBD patients.17
Mucosa Protectives
The intestinal inflammatory process in IBD not only
affects the cells within the lamina propria, but has
also a major impact on the function of the epithelial
cells  of  the  mucosa.  Some  therapeutic  strategies
particularly  aim  at  restoring  the  epithelial  integrity
and function, while others are installed to attenuate
the mucosal inflammation. In the end, most of the
substances appear to do both.
Sucralphate
This non-absorbable aluminium salt of sucrose octa-
sulphate  has  the  capability  to  selectively  bind  to
damaged  and  ulcerated  tissue,  thereby  providing
protection  against  noxious  agents.  Sucralphate  is
particularly  known  from  the  treatment  of  upper
gastrointestinal inflammation  and ulceration, but  in
several clinical trials attempts were made to assess its
efficacy  in  distal  colitis  and  proctitis  (reviewed  in
Polson and Misiewicz18). Topical application of sucral-
phate enemas to patients with active distal UC was
reported to be of variable success. Apparently some
benefit  may  be  achieved,  i.e.  resolution  of  rectal
bleeding  and  improvement  of  histological  appear-
ance. In general, however, sucralphate seems to be
less effective than prednisolone and of limited use in
the treatment of distal colitis.
Short chain fatty acids
Access to colonocyte fuels is essential for the epithe-
lial healing process. Short chain fatty acids, such as
propionate,  acetate,  and  butyrate,  which  are  pro-
duced by bacterial fermentation of complex carbohy-
drates or oligosaccharide fibres, are preferred nutri-
ents for colonocytes.15 In UC patients, utilization of
particularly  butyrate  seems  to  be  impaired,  pre-
sumably not  due to  deficiencies in the  b -oxidation
pathway in the intestinal mucosa, but as a result of a
high  luminal  content of sulphate-reducing bacteria,
which produce sulphide that interferes in the butyr-
ate-oxidation (see Fig. 1).
Application of butyrate has been successfull in the
treatment  of  colorectal  neoplasia,  because  of  its
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and  to  induce  their  differentiation  (see  Fig.  1).
Likewise,  treatment  of  active  UC  with  butyrate
enemas has been reported with considerable success
regarding  endoscopic  and  histologic  improvement,
without major side effects,19 although negative results
have  been  reported  as  well.  Many  of  the  studies,
however, were preliminary or uncontrolled trials and
larger  decisive  studies  are  needed.  A  number  of
biochemical  studies  do  provide  circumstantial  evi-
dence, however, that butyrate-related treatment could
be  of  benefit  to  patients  with  distal  colitis.  For
instance,  it has  been found to reduce apoptosis of
colonocytes, as well as pro-inflammatory cytokine (IL-
8) production by epithelial cells and mucosal inflam-
mation, and to  increase colonic mucin  production,
and  adhesion  molecule  (ICAM-I)  and  HLA  class  I
expression. These phenomena do indicate that butyr-
ate  is able to  modulate the intestinal inflammatory
process. Perhaps (a combination of) a oligosaccharide
fibres-rich  diet,  topical  installation  of  butyrate,  and
inhibition of bacterial sulphidogenesis might prove to
be of clinical benefit in UC, as has to be shown in
better controlled clinical studies.
Long chain (n-3) fatty acids
Arachidonic acid metabolites, like prostaglandin PGE2
and  thromboxane TXA2 generated  by  the  cycloox-
ygenase pathway and leukotriene LTB4 produced by
5-lipoxygenase,  are  known  to  contribute  to  the
inflammatory  process in IBD. Specific  inhibitors of
both oxygenases have been found to either aggravate
the inflammation in animal models and patients, or to
be  clinically  ineffective.  More  encouraging  results
have been obtained by the oral administration of fish
oil and evening primrose oil, which replace the long
chain n-6 eicosanoid (arachidonic) fatty acids by n-3
eicosapentaenoic/docosahexaenic  acids  and  g -lino-
leic  acid,  respectively.  These  substances  compete
with  the  same  oxygenases  and  finally  yield  in  the
production of less potent inflammatory mediators as
LTB5,  which  is  less  chemotactic  and  activating  for
neutrophils  than  LTB4,  and  PGE1 which  inhibits
arachidonic  acid  release  (see  Fig.  1).  Besides  the
numerous  biochemical  studies  which  indicate  a
reduction in the intestinal inflammatory process, the
majority  of  clinical  intervention  studies  revealed  a
moderate  to  good  response,  with  endoscopic  and
histologic improvement and a steroid-sparing effect in
UC.15
The major problem with the substances, however,
are the unpleasant taste and the almost unacceptable
side-effects  as flatulence,  diarrhoea, heartburn,  etc.
Most recently, new enteric-coated preparations have
been developed which reduce both the therapeutic
dose and the side-effects. This new fish oil preparation
was found to significantly reduce the relapse rate of
patients with Crohn’s disease in remission, as deter-
mined in a 1-year controlled study.20 Although similar
studies were found to be less impressive and there
was  some  debate  on  the  fish  oil  composition  and
patient  inclusion  criteria,  these  results  are  very
promising  and  need  to  be  expanded  by  further
studies.
Although many aspects of the biochemical mecha-
nisms which are elicited by long chain n-3 fatty acids
have  been  elucidated,  the  exact  anti-inflammatory
working profile is still unravelled. Apparently, not only
a shift takes place towards less harmful prostaglandins
and  leukotrienes,  but  there  is  also  compelling  evi-
dence that dietary fish oil supplementation is able to
directly or indirectly downregulate pro-inflammatory
cytokines,  like  TNF ,  IL-1  and  IL-621 (see  Fig.  1).
Furthermore, there are some  indications that  these
dietary  lipids  are  able  to  improve  the  antioxidant
status  of  tissues.22 In  that  context,  one  interesting
aspect might need some further attention. Many of
the  long  chain  n-3  fatty  acid  preparations  contain
antioxidants, like vitamin E, to prevent lipid peroxida-
tion of the oils. The contribution of these antioxidants
to  the  attenuation  of  the  inflammatory  response
might be worthwhile pursuing.
Finally,  a  recent  study  with  a  bacterial  cell  wall
induced colitis in rats showed that a complete enteral
diet containing the combination of fish oil and diverse
oligosaccharides was as effective as sulphasalazine in
improving the chronic intestinal inflammation.23
Conclusion and Perspectives
Although there has been considerable progress in the
understanding of metabolic and oxidative processes
and how they relate to tissue damage in IBD, their
translation into clinical practice has yet to be made.
The  initial  enthusiasm  for  innovative  mucosa  pro-
tectives  and antioxidant agents  in IBD  therapy  has
been  somewhat  tempered,  because  of  the  lack  of
efficacy or  of  large  confirmative  controlled clinical
trials. At present we may conclude that their position
in the therapeutic armament for IBD will be, at their
best, in the form of adjunctive (dietary) therapy.
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